Aurinia Pharmaceuticals (AUPH) Short-term Investments (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 9 years of Short-term Investments data on file, last reported at $337.8 million in Q1 2026.

• Quarterly Short-term Investments rose 37.04% year-over-year to $337.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $337.8 million (up 37.04% YoY) and the FY2025 annual result came in at $317.8 million, up 15.54% from the prior year.
• Short-term Investments grew to $337.8 million in Q1 2026, from $317.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $337.8 million in Q1 2026 to a low of $240.1 million in Q2 2022.
• A 5-year average of $284.0 million and a median of $286.2 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments jumped 49.3% — and 2025, when it fell 11.76%.
• Tracing AUPH's Short-term Investments over 5 years: stood at $295.2 million in 2022, then rose by 2.17% to $301.6 million in 2023, then declined by 8.81% to $275.0 million in 2024, then increased by 15.54% to $317.8 million in 2025, then increased by 6.29% to $337.8 million in 2026.
• The last three Short-term Investments figures came in at $337.8 million (Q1 2026), $317.8 million (Q4 2025), and $278.6 million (Q3 2025), per Business Quant data.